AI scribe adoption linked to modest reductions in EHR, documentation time: study
Emily Olsen / healthcaredive - Clinicians’ use of an AI scribe was associated with 13 fewer minutes each day inside electronic health records and 16 fewer minutes on documenting patient care, according to the research published in JAMA.
AI Summary: A multi‑site study found adoption of AI medical scribes yields small but consistent reductions in electronic health record documentation and clinician charting time. Hospitals reported time savings and workflow adjustments, but gains were modest — enough to raise eyebrows, not replace human scribes or magic.
- Companies push AI beyond notes — coding, decision support, geriatric assessments (3)
- Frontline adoption: health systems pilot ambient AI, Epic integration underway (5)
- Multisite study finds AI scribes slightly cut clinicians' EHR time (3)
- All Other Stories
Companies push AI beyond notes — coding, decision support, geriatric assessments
Frontline adoption: health systems pilot ambient AI, Epic integration underway
Multisite study finds AI scribes slightly cut clinicians' EHR time
All Other Stories
Group sues CMS for details on Medicare AI prior authorization pilot
Andrew Cass / beckershospitalreview - Digital rights advocacy organization the Electronic Frontier Foundation has filed a Freedom of Information Act lawsuit against CMS seeking information on how the AI algorithms work in its traditional Medicare prior authorization pilot. CMS’ Wasteful and I…
AI Summary: A coalition of tech and privacy groups has sued CMS seeking detailed records about a Medicare pilot that uses AI to automate prior authorization decisions. Plaintiffs argue the agency failed to provide transparency on algorithms, data inputs and patient safeguards, demanding documents to assess legal, safety and fairness risks before the program expands.
WHOOP Secures $575M, Reaches $10B Valuation
Marissa Plescia / medcitynews - WHOOP’S Series G round was led by Collaborative Fund and includes participation from 2PointZero Group, Qatar Investment Authority, Cristiano Ronaldo and LeBron James.The post WHOOP Secures $575M, Reaches $10B Valuation appeared first on MedCity News.
AI Summary: Wearable fitness company Whoop closed a $575 million funding round that values the business at roughly $10 billion, attracting strategic partners including Abbott and health systems like Mayo Clinic. The cash infusion underwrites an aggressive hiring spree and product expansion as Whoop doubles down on clinical collaborations and scaling its sensor and analytics platform.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…
AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.
CMS: This year's open enrollment brought fewer signups, higher premiums
fiercehealthcare - The administration's official numbers on the 2026 Open Enrollment Period outlined drops in new customers and automatic re-enrollment, the latter of which CMS said stemmed from its crackdown on improper enrollments. Average monthly premiums also increased …
AI Summary: CMS data show this year's ACA open enrollment produced fewer new signups while benchmark premiums climbed, nudging many consumers into higher‑deductible plans. Enrollment sits near 23.1 million for 2026, but the mix of coverage is tilting toward cost‑sharing over comprehensiveness, raising concerns about affordability and surprising out‑of‑pocket shocks for vulnerable families.
What you should know about the new COVID-19 'Cicada' variant
medicalxpress - A new COVID-19 variant that some have dubbed the "Cicada" variant is quietly spreading across the globe, carrying an unusually high number of mutations that could help it slip past existing immunity, public health experts say. The strain of SARS-CoV-2, ca…
AI Summary: A newly identified SARS‑CoV‑2 lineage nicknamed "Cicada" is showing signs of increased spread, prompting CDC tracking and expert concern. Public health officials advise heightened surveillance, updated testing and genomic sequencing to determine transmissibility, immune escape and clinical impact, while researchers rush to characterize the variant’s risks and inform any needed response.
The new cholesterol guideline: What to know
medicalxpress - For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and jointly published in the Journal of the American Colleg…
AI Summary: Updated cholesterol guidance proposes shifts in testing strategy and risk assessment that may change timing and targets for lipid screening. Clinicians and patients should expect revised thresholds and more personalized testing intervals as the guideline aims to better align prevention with individual cardiovascular risk—so yes, your testing schedule might get a makeover.
- Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease (3)
- OTHER — Triglyceride drug failed to reduce arterial plaque (1)
- Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI (3)
- Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies (3)
- All Other Stories
Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease
OTHER — Triglyceride drug failed to reduce arterial plaque
Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI
Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies
All Other Stories
Teens are driving the demand for online abortion pills via telehealth
medicalxpress - Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people aged 18 to 24 are ordering medication abortion at much higher rates than older adults.
AI Summary: Telehealth provision of medication abortion has surged, reducing travel for many and prompting a noticeable uptick in online requests from teenagers. Reports show virtual care is reshaping access patterns and forcing healthcare systems and regulators to confront new realities around remote prescribing, confidentiality, and youth access to reproductive services.
NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories
At ELCC: late‑breaking trials reshaping clinical practice
OTHER: misc lung oncology studies, regulatory and surgical updates
Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care
Voices from ELCC: clinicians share breakthroughs and practical takeaways
All Other Stories
When it comes to surgery, your doctor's leadership skills play a crucial role
medicalxpress - You're scheduled for surgery next week. You've likely looked up your surgeon's credentials, years of experience, and perhaps even patient reviews. You want reassurance that your surgeon has steady hands, deep expertise, and a thorough command of the proce…
AI Summary: New research links a surgeon’s leadership and team‑management skills to measurable differences in operating‑room performance and patient outcomes. Hospitals are being nudged to treat leadership training as clinical skill development rather than optional soft training — because apparently who’s in charge matters when someone’s insides are on the line.
Global study estimates over 250,000 meningitis deaths in 2023, with young children bearing a heavy toll
medicalxpress - In 2023, 259,000 people died from meningitis and 2.5 million people were infected with the disease globally, suggests a study published in The Lancet Neurology. Although death and infection rates have declined significantly since 1990, progress is insuffi…
AI Summary: A worldwide mortality analysis estimates more than 250,000 deaths from meningitis in 2023, with young children bearing the heaviest toll. The findings underline gaps in vaccination, surveillance and outbreak preparedness, and call for accelerated prevention efforts—particularly on campuses and in high‑risk populations—before the predictable heartbreak rolls around again.
Continuous wearable monitoring reduces time with low oxygen after surgery, study finds
medicalxpress - Patients continuously monitored after surgery experienced significantly less time with dangerously low oxygen levels compared to those monitored using routine spot checks, a new study from Wake Forest University School of Medicine found.
AI Summary: An HCA Florida hospital has named a new chief financial officer as part of a leadership shakeup aimed at stabilizing operations and tightening financial oversight. The appointment signals management’s focus on fiscal discipline and strategic planning amid ongoing industry pressures—because nothing says “confidence” like swapping out the person who signs the checks.
When everyday tasks become harder: Early clues to Alzheimer's disease
medicalxpress - For many older adults, life is full of routines. Making breakfast, paying bills, shopping, driving, managing appointments and keeping track of medications are tasks done almost automatically. For most, these routines run smoothly, but for some, small disr…
AI Summary: A study finds that small, progressive difficulties with routine daily tasks can be early indicators of Alzheimer’s disease, preceding obvious cognitive symptoms. Tracking functional changes may enable earlier detection, intervention and planning, shifting attention from memory tests alone to how people manage everyday life — yes, the missing teaspoons matter.
- Everyday task declines: early, subtle signals of pending Alzheimer’s (4)
- Labs and trials wrestle with hopeful but faltering Alzheimer's therapies (3)
- Sleep, blood and life-history markers expose rising dementia risk (4)
- All Other Stories
Everyday task declines: early, subtle signals of pending Alzheimer’s
Labs and trials wrestle with hopeful but faltering Alzheimer's therapies
Sleep, blood and life-history markers expose rising dementia risk
All Other Stories
Two States Sue Cord Blood Bank Over False Advertisements
Sarah Kliff and Azeen Ghorayshi / nytimes - The attorneys general of Texas and Arizona contend that Cord Blood Registry, which stores umbilical cord cells, profited from misleading new parents.
AI Summary: Two state attorneys general filed lawsuits alleging a cord‑blood bank made false or misleading claims about the future therapeutic value of stored units. The actions seek consumer remedies and penalties, challenging marketing that regulators say may have led families to pay for services based on overstated promises about potential medical uses.
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.
Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia
esmo - Findings from the RECITE study
AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.
UK government recommends maximum two hours of screen time for younger children: What the evidence says
medicalxpress - New UK government guidance recommends that screen time for children under two should be avoided, except for shared activities such as video calls. For children aged two to five, a maximum of an hour a day is suggested. The guidance also outlines that watc…
AI Summary: The UK government updated child‑health guidance recommending strict limits on young children’s screen time, citing evidence linking excessive use to delayed development and poorer sleep. The guidance urges parents and caregivers to prioritize interactive, non‑screen activities and age‑appropriate limits while acknowledging modern practicalities for families.
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong
abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …
AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.
FDA approves 1st weekly basal insulin for Type 2 diabetes
Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…
AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.